BPC-157: Mechanisms, Research Findings & What Studies Show (2026)

BPC-157 is a synthetic pentadecapeptide, meaning a chain of exactly 15 amino acids. Its sequence copies part of a larger protein found in human gastric juice, which is where the name Body Protection Compound comes from. The BPC-157 peptide carries no FDA approval, no pharmacopoeial monograph, and no approved product status in any country. It is sold and studied strictly as a research compound.

Most of what gets said about it traces back to rat studies published since 1993. This guide covers the mechanisms researchers have mapped, what the animal and cell data show, where the human evidence stops, and how the regulatory picture changed in July 2026.

Key Takeaways

• BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice, first described by researchers at the University of Zagreb in 1993.
• Preclinical work points to three main pathways: angiogenesis via VEGFR2, nitric oxide signaling via eNOS, and growth hormone receptor upregulation in tendon cells.
• The molecular target BPC-157 binds to has never been identified. The FDA said so plainly in its May 2026 evaluation.
• Across every published clinical study, BPC-157 has been given to roughly 81 people in total.
• On 23 July 2026, an FDA advisory committee voted 8 to 6 to recommend BPC-157 for compounding. The vote is non-binding and changes nothing yet.

What Is BPC-157?

BPC-157 is a laboratory-made peptide built from 15 amino acids in the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a fragment of Body Protection Compound, a protein isolated from human gastric juice. Researchers at the University of Zagreb first described it in 1993 as a possible free radical scavenger and organoprotection mediator.

It also goes by Bepecin and PL-14736 in older literature, and carries CAS number 137525-51-0 with a molecular weight of 1,419.5 g/mol. That naming mess is more important than it sounds. The FDA has flagged that BPC-157 is a common name with no formally assigned chemical standard behind it, and that several different salts and derivatives get sold commercially under the same three-word label. Free base and acetate forms are chemically distinct substances.

In research form, it is a white to off-white lyophilized powder, soluble in water at 5 mg/mL, with a melting point above 232°C.

Why It’s Studied: Stability in Gastric Juice

Most peptides fall apart in the stomach. BPC-157 does not, and that single property is why it got attention in the first place.

Work by Veljaca and colleagues in 1995 found the peptide resistant to hydrolysis in human gastric juice under laboratory conditions. Ordinary peptides get cleaved by digestive enzymes within minutes, which rules out oral routes for most of them. A peptide that survives that environment opens up study designs other compounds cannot support.

That stability carries into handling. Lyophilized BPC-157 stays stable at room temperature for around three weeks, though storage below -18°C is recommended because moisture cuts long-term stability sharply. Once reconstituted, solutions hold for two to three weeks at 4°C and three to four months at -20°C.

Worth noting the limit of that finding. Surviving gastric juice in a test tube says nothing about whether the peptide reaches the bloodstream intact in a living animal.

How BPC-157 Works: Mechanisms of Action

Researchers have traced BPC-157 activity to several overlapping pathways: new blood vessel formation through VEGFR2, nitric oxide production through eNOS, growth hormone receptor upregulation in tendon cells, and cell migration through FAK and paxillin. One honest caveat sits underneath all of it. The receptor BPC-157 binds to has never been found.

Angiogenesis and the VEGFR2 Pathway

Hsieh and colleagues reported in 2017 that BPC-157 drives new blood vessel growth by changing how cells handle a receptor they already have.

Their team used a chick chorioallantoic membrane assay and an endothelial tube formation assay, and saw vessel density rise in both. In rats with hind-limb ischemia, laser Doppler scanning showed faster blood flow recovery. Human endothelial cells showed more VEGFR2 at the mRNA and protein levels, while VEGF-A, the growth factor that normally triggers that receptor, stayed flat.

The interesting part came next. BPC-157 pushed VEGFR2 into the cell, and dynasore, which blocks that internalization step, shut down both the receptor signaling and the tube formation. The peptide appears to work by moving the receptor inside the cell, where the VEGFR2-Akt-eNOS cascade fires.

Nitric Oxide System Modulation

Nitric oxide controls how blood vessels widen and narrow, and BPC-157 interacts with that system heavily enough that some researchers treat it as the core mechanism.

A 2020 study by the same Taiwanese group tested BPC-157 on isolated rat aorta and found concentration-dependent vasodilation. Strip the endothelium away, and most of the effect goes with it. Adding L-NAME, a nitric oxide synthase blocker, or hemoglobin, which mops up nitric oxide, canceled the vasodilation. The pathway they mapped runs Src to Caveolin-1 to eNOS, and eNOS phosphorylation showed up within 30 minutes of exposure.

Growth Hormone Receptor Upregulation

Chang and colleagues ran a cDNA microarray on rat tendon fibroblasts and found growth hormone receptor among the most heavily upregulated genes after BPC-157 exposure.

Working with fibroblasts isolated from Sprague-Dawley rat Achilles tendon, they saw receptor expression climb in a dose-dependent way across 0.1, 0.25 and 0.5 µg/mL over 24 hours, confirmed at mRNA and protein levels. Adding growth hormone to treated cells then increased proliferation, and JAK2, the signaling molecule downstream of that receptor, was activated in a time-dependent pattern. Their conclusion: BPC-157 makes tendon cells more responsive to growth hormone the body already has. The full study is available in Molecules.

The FAK-Paxillin Pathway and Tendon Fibroblasts

Focal adhesion kinase and paxillin are the proteins cells use to grip surfaces and pull themselves along, so they show up whenever tissue repair involves cells physically moving.

Chang and colleagues reported in 2011 that BPC-157 promoted tendon outgrowth, cell survival, and cell migration in rat tendon fibroblasts. Across a concentration range of 100 nM to 1 µM, FAK and paxillin phosphorylation peaked at the top of that range. Wang and colleagues later found the same pattern in skeletal muscle cells, with paxillin and vinculin both rising.

Gut-Brain Axis and Neurotransmitter Effects

The odd finding in the BPC-157 literature is that a gut peptide given peripherally produces measurable changes in the brain.

Tohyama, Sikirić and Diksic used autoradiographic tracer measurements to show that peripheral BPC-157 changed serotonin synthesis in specific brain regions of rats, with the nigrostriatal area standing out. Jelovac and colleagues reported in Biological Psychiatry that the peptide blocked amphetamine-induced stereotypy and interfered with haloperidol-induced dopamine receptor supersensitivity. Sikirić’s group frames this as a bidirectional gut-brain axis effect, still a hypothesis under investigation.

The gap under all of this: in its May 2026 evaluation, the FDA stated that the molecular targets for BPC-157 have not been identified and that its mechanisms of action remain poorly understood, which makes the biological plausibility of the reported effects hard to assess. A December 2025 preprint by Schlosser proposes an answer, modeling BPC-157 as a polyproline II helix that binds the SH3 domains of Src family kinases. Half the peptide’s N-terminal segment is proline, which fits that shape. The work is computational so far, with laboratory validation still to come.

Research Findings: What Studies Show

Nearly the entire BPC-157 evidence base is derived from rats and mice, published largely by a single Croatian research group since 1993. Here is what each research area contains.

Tendon, Ligament and Muscle Healing

This is the most replicated area. Staresinic and colleagues reported in the Journal of Orthopedic Research in 2003 that BPC-157 accelerated healing of transected rat Achilles tendon and stimulated tendocyte growth in culture. Cerovecki’s team reported improved ligament healing in rats in the same journal in 2010. Novinscak and colleagues reported benefit in a rat muscle crush injury model in 2008.

The 2025 systematic review in HSS Journal summarised the preclinical picture as improved functional, structural and biomechanical outcomes across muscle, tendon, ligament and bone injuries.

Gastrointestinal Research

Gut work is where BPC-157 started, and the reported effect sizes are large.

Sikirić and colleagues found in 1997 that rats pre-treated or co-treated with BPC-157 showed stomach and intestinal lesions reduced by more than 75% after high doses of aspirin, diclofenac or indomethacin. Klicek’s team reported in 2008 that surgically created colonic fistulas in treated rats measured roughly 40% smaller from day three onward, and appeared resolved by day 28 while control fistulas had shrunk under 25%.

One catch the FDA highlighted: neither study established a dose-response relationship, because doses a thousand-fold apart produced the same result.

Nerve and Tissue Regeneration

Gjurasin and colleagues reported improved nerve healing and function in rats after sciatic nerve transection, and Perovic’s team published spinal cord injury recovery data in 2022. Vukojević and colleagues applied BPC-157 at 10 µg/kg to the operated area in rats after bilateral carotid clamping and reported recovery from hippocampal ischemia and reperfusion injury.

Bone and Joint Models

Bone and joint data are thinner than the tendon work. The HSS Journal review grouped bony injury outcomes with broader musculoskeletal findings without isolating a body of fracture-specific studies. On the clinical side, that same review found a single retrospective report in which 7 of 12 patients receiving an intra-articular injection for chronic knee pain described relief lasting beyond six months. No control group, no blinding, self-reported outcome.

Evidence Quality: The Numbers Nobody Prints

Search PubMed, Embase, and the Cochrane database, as FDA reviewers did through December 2025, and five clinical studies come back. Total human exposure across all of them is roughly 81 people.

Study	Subjects	Route	Reported finding
Veljaca 2002/2003	24 healthy	Rectal enema, 8 days	Headache and flatulence most common; peptide not detected in plasma
Ruenzi 2005	53 randomized, ulcerative colitis	Rectal enema, 2 weeks	Between-group difference not statistically significant
Lee & Padgett 2021	17, knee pain	Intra-articular	Retrospective, self-reported relief
Lee 2024	12, interstitial cystitis	Intravesical	Pilot study
Lee & Burgess 2025	2 healthy	Intravenous	Pilot safety study

The Ruenzi trial deserves a closer look because it is the only randomized, placebo-controlled study ever run. Disease activity index improved by 3.2 points in the BPC-157 arm and 1.6 points in the placebo arm. The estimated difference between groups was 1.6 points, with a 95% confidence interval from -4.84 to 1.62. That interval crosses zero, meaning the result is consistent with no benefit, and it has never been published beyond a conference abstract.

One registered trial exists on ClinicalTrials.gov, a Phase 1 study of 42 healthy subjects in Mexico. No results were ever posted.

Potential Benefits Examined in Research

Each item below reflects what researchers reported in animal or cell models. None of it has been established in humans, and none of it should be read as an expected outcome.

• Wound and soft tissue repair. Rat studies report faster healing of transected Achilles tendon, injured ligament, and crushed muscle.
• Gastric mucosal protection. In rats given high-dose NSAIDs, BPC-157 was associated with lesion reduction above 75%.
• Angiogenesis. Cell and chick embryo assays show increased vessel density, with rat hind-limb ischemia models showing faster blood flow recovery.
• Nerve recovery. Rodent models of sciatic nerve transection, spinal cord injury and brain ischemia report functional improvement.
• Liver protection in toxin models. Rats challenged with carbon tetrachloride or repeated diclofenac showed less necrosis and lower enzyme elevation.
• Neurotransmitter modulation. Peripheral dosing changed region-specific brain serotonin synthesis in rats and interfered with drug-induced dopamine disturbances.

Reported Side Effects and Safety Considerations

Formal animal toxicology looks reassuring on short-term measures and silent on long-term ones. Human safety data is close to absent.

What Preclinical Safety Data Shows

Xu and colleagues published the only structured toxicology package in 2020. A single intramuscular dose produced no signs of acute toxicity or organ changes at 20 mg/kg in rats and 10 mg/kg in dogs, which became the no-observed-adverse-effect levels for that route.

Genotoxicity came back clean across the board: negative in bacterial reverse mutation testing across five Salmonella strains, negative for chromosome aberrations in Chinese hamster lung cells, and negative in a mouse bone marrow micronucleus assay. Pregnant rats dosed between gestation days 6 and 15 showed no effect on fetal weight, litter counts, or malformation rates.

The 28-day repeat-dose study raised two signals. Clotting time shifted in opposite directions across species, shortening in rats and lengthening in dogs. Liver-associated markers moved as well, with serum ALT, glucose and triglycerides rising.

Unknowns and the Missing Long-Term Human Data

The list of things nobody has measured runs longer than the list of things they have.

No carcinogenicity study of BPC-157 exists. No human pharmacokinetic data exists for oral, subcutaneous, nasal, or transdermal routes. In the two rectal enema studies where plasma was sampled, the peptide went undetected, raising the question of whether it reaches circulation by that route at all.

The FDA’s central safety concern is immunogenicity. Peptides can clump into aggregates, and aggregation is a known risk factor for immune responses ranging from harmless antibodies to serious reactions. No study has formally investigated immunogenicity for BPC-157 products.

The FDA Adverse Event Reporting System held exactly three BPC-157 reports as of December 2025. The most specific involved a 40-year-old woman using a BPC-157 and TB-500 product labeled for research purposes only, who developed diffuse skin hyperpigmentation and darkening of the gums. The reaction reproduced identically when she used the product again two weeks later, and resolved when she stopped.

Purity and Sourcing Risks in an Unregulated Market

This is where FDA reviewers were bluntest, and it applies to most BPC-157 material sold online.

Reviewing certificates of analysis from commercial suppliers, they found that most contain purity testing and nothing else. No impurity limits. No identification of what the impurities are. No bioburden or bacterial endotoxin results, the tests that matter for anything prepared as an injectable. Their conclusion: the potential for immunogenicity from impurities and aggregates cannot be ruled out.

Solid-phase peptide synthesis produces predictable by-products: truncated sequences, incomplete couplings, leftover solvents and coupling reagents. A purity percentage alone tells you nothing about which of those are present. For research work, a full quality panel matters, and a lot-matched certificate you can check against the vial in front of you matters more than a generic figure on a product page. Kylo’s lot-matched COA library shows what that looks like.

Legal and Regulatory Status

BPC-157 is not FDA-approved, cannot be legally sold as a dietary supplement, and is prohibited for athletes under WADA. On 23 July 2026, an FDA advisory committee voted 8 to 6 to recommend adding it to the compounding list. That vote is non-binding and current restrictions still stand.

Not an approved drug. BPC-157 appears in no country’s approved drug database and holds no monograph in the US, European, Japanese, or International Pharmacopeias. New Zealand’s Medicines Classification Committee proposed in 2023 that it be classed as a prescription medicine.

The compounding category change. In September 2023, the FDA placed BPC-157 in Category 2, covering bulk substances that may present significant safety risks if used in compounding. On 11 May 2026, FDA reviewers completed an evaluation recommending against adding BPC-157 to the 503A Bulks List, citing poor chemical characterization, insufficient safety data, and lack of evidence for effectiveness in ulcerative colitis, the use they assessed. 

On 23 July 2026, the Pharmacy Compounding Advisory Committee voted against that recommendation, 8 to 6 with one abstention. KPV, reviewed the same morning, cleared by the identical margin, and our KPV research guide covers that compound in detail. Formal rulemaking with public comment still has to run before anything changes, and the FDA is free to decline.

Banned in sport. BPC-157 sits in class S0, Non-Approved Substances, on the WADA Prohibited List, prohibited at all times both in and out of competition. It also appears on the Department of Defense Prohibited Dietary Supplement Ingredients List. Enforcement is active: a 19-year-old American speed skater received a one-year sanction in 2024, and volleyball player Emma Brooks received four years from the Canadian Center for Ethics in Sport.

Why research-use-only is crucial. Operation Supplement Safety, the Department of Defense program, states that BPC-157 is an unapproved drug and not a dietary ingredient, and that it cannot be legally prescribed or sold over the counter. That program makes a point every researcher should absorb: a research-use-only label describes the legal status of the material, and it grants no permission for human use.

BPC-157 vs TB-500

These two get discussed together constantly, and the FDA reviewed both on the same day in July 2026.

	BPC-157	TB-500
Structure	15 amino acids, fragment of Body Protection Compound	Fragment related to thymosin beta-4
Origin	Human gastric juice protein	Thymosin beta-4, a naturally occurring protein
Studied mechanism	VEGFR2 internalization, nitric oxide, growth hormone receptor	Cell migration and actin binding
FDA use evaluated, July 2026	Ulcerative colitis	Wound healing
PCAC vote, 23 July 2026	8 to 6 in favor	8 to 6 in favor
WADA status	Prohibited, class S0	Prohibited

The pairing is common enough that FDA case reports involving both compounds are hard to attribute to either one, worth remembering when reading combined-product safety anecdotes. Any research design that separates the two compounds depends on knowing exactly what is in each vial, and Kylo Peptides matches identity and purity results to the lot number printed on it.

Frequently Asked Questions

Can you buy BPC-157 over the counter? 

No, Operation Supplement Safety states that BPC-157 is an unapproved drug and not a dietary ingredient, and that it cannot be legally prescribed or sold over the counter in the United States. Material sold online is offered for laboratory research use only.

Does BPC-157 work immediately? 

No published human data answer this. Pharmacokinetic work in animals found a half-life of 5.3 minutes in dogs and 15.2 minutes in rats after a single intravenous dose, so the compound clears quickly. In rat studies, measurable tissue changes typically appeared over days.

Is it safe to take BPC-157 daily? 

There is no safety basis for daily human use. The longest human study on record ran two weeks by rectal enema. No carcinogenicity data exists, and FDA reviewers concluded that available clinical safety information cannot characterize the compound’s safety profile.

Is BPC-157 FDA approved or legal? 

BPC-157 is not FDA approved for any use and appears in no approved drug database in any country. It has been in the FDA’s Category 2 since September 2023, which covers substances that may present significant safety risks in compounding. The July 2026 advisory vote was a recommendation only.

What is BPC-157 used for? 

In published research, it has been studied in animal models of tendon, ligament and muscle injury, gastric and intestinal lesions, nerve and spinal cord injury, and liver toxicity. The clinical literature covers ulcerative colitis, knee pain, and interstitial cystitis in small pilot work.

How is BPC-157 used in research settings? 

Laboratory work uses lyophilized BPC-157 reconstituted in sterile solution for in vitro assays such as endothelial tube formation and fibroblast migration, and for in vivo rodent injury models. Researchers typically verify identity and purity against a lot-matched certificate of analysis before running an assay.

Does BPC-157 damage the liver? 

No human liver data is available. Rat studies report the opposite direction, with BPC-157 reducing liver necrosis and enzyme elevation after carbon tetrachloride or repeated diclofenac challenge. Against that, a 28-day repeat-dose toxicity study in rats and dogs recorded rising serum ALT, glucose and triglycerides in treated animals.

What does BPC-157 do to the heart? 

Cardiac effects in animals are documented but poorly understood, and no human cardiac data is available. Balenović and colleagues reported that BPC-157 inhibited methyldigoxin-induced arrhythmias in rats through the nitric oxide system. Rodent work also reports counteraction of drug-induced QT prolongation. None of that has been tested in people.

Research Summary

The BPC-157 evidence base is deep in one direction and shallow in the other. Thirty years of rodent and cell work consistently report tissue repair effects across tendon, gut, nerve and vascular models, with three mechanisms mapped in reasonable detail. That volume of replication is real and deserves attention.

Alongside it sits a near-total absence of human evidence. Roughly 81 people across five studies, one randomized trial whose result was consistent with no benefit and which never made it past a conference abstract, no carcinogenicity data, and no identified molecular target.

The July 2026 advisory vote moved the regulatory conversation forward without changing the science underneath it. BPC-157 remains an unapproved drug, prohibited in sport, and sold legally in the United States only as material for laboratory research use, not for human or veterinary use.

References

1. Sikirić P, et al. A new gastric juice peptide, BPC. Journal of Physiology-Paris. 1993;87(5):313-327.
2. FDA Briefing Document: Evaluation of BPC-157-Related Bulk Drug Substances for Inclusion on the 503A Bulk Drug Substances List. Pharmacy Compounding Advisory Committee, 11 May 2026.
3. Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077.
4. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780.
5. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333.
6. Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. 2020;10:17078.
7. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal. 2025;21(4):485-495.
8. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. Journal of Orthopaedic Research. 2003;21(6):976-983.
9. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010;28(9):1155-1161.
10. Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC157 is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide system. Journal of Pharmacological Sciences. 2008;108(1):7-17.
11. Vukojević J, Vrdoljak B, Malekinušić D, et al. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain and Behavior. 2020;10(8):e01726.
12. Jelovac N, Sikiric P, Rucman R, et al. A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine. Biological Psychiatry. 1998;43(7):511-519.
13. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182.
14. Ruenzi M, Stolte M, Veljaca M, et al. A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in mild-to-moderate ulcerative colitis. Gastroenterology. 2005;128:A584.
15. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine. 2021;27(4):8-13.
16. Balenovic D, Bencic ML, Udovicic M, et al. Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with the NO system. Regulatory Peptides. 2009;156(1-3):83-89.
17. Schlosser SK. BPC-157 binding to SH3 domains and activation of Src family kinases. Research Square preprint. December 2025. DOI: 10.21203/rs.3.rs-8167242
18. Operation Supplement Safety. BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products. US Department of Defense.

Disclaimer: BPC-157 is not FDA-approved and is not a dietary ingredient. The research cited here is animal, cell, and small pilot work, and nothing in this article is a treatment claim or medical advice. Kylo Peptides supplies research materials for laboratory use only, not for human or veterinary consumption.